Hospital morbidity associated with the natural history of heroin use

Journal of Opioid Management

Volumn 4, Issue 5, 2008, Pages 321-327

  Tait, Robert J ^a   Hulse, Gary K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Heroin; Hospital; Morbidity; Naltrexone

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; DIAMORPHINE; METHADONE; NALTREXONE; OPIATE; SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; AUSTRALIA; CANNABIS ADDICTION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG IMPLANT; FEMALE; FOLLOW UP; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPIATE ADDICTION; SUSTAINED RELEASE FORMULATION;

EID: 57149112334     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0036     Document Type: Article

References (38)

1. Hulse GK, English DR, Milne E, et al.: The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999; 94: 221-229.
2. Warner-Smith M, Darke S, Day C: Morbidity associated with non-fatal heroin overdose. Addiction. 2002; 97: 963-967.
3. Hulse GK, Basso MR, Wodak A: The injecting drug user. In Hulse GK, White Jason M, Cape G, (eds.): Management of Alcohol and Drug Problems. Melbourne: Oxford University Press; 2002: 241-257.
4. Darke S, Sims J, McDonald S, et al.: Cognitive impairment among methadone maintenance patients. Addiction. 2000; 95: 687-695.
5. Gossop M, Marsden J, Stewart D, et al.: The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction. 2003; 98: 291-303.
6. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000; 67: 347-364.
7. Stewart D, Gossop M, Marsden J. Reductions in non-fatal overdose after drug misuse treatment: Results from the National Treatment Outcome Research Study (NTORS). J Subst Abuse Treat. 2002;22:1-9.
8. Henderson N, Ross J, Darke S, et al.: Longitudinal studies of dependent heroin users in Australian: Feasibility and benefits. Australia: National Drug and Alcohol Research Centre, 2002.
9. Darke S, Hall W: Heroin overdose: Research and evidence based intervention. J Urban Health. 2003; 80: 189-200.
10. Darke S, Ross J, Hall W: Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal over-dose. Addiction. 1996; 91: 405-411.
11. Hser Y-L, Hoffman V, Grella CE, et al.: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001; 58: 503-508.
12. Hulse GK, Tait RJ, Comer SD, et al.: Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005; 79: 351-357.
13. Ngo H, Tait R, Arnold-Reed D, et al.: Mental health outcomes following naltrexone implant treatment for heroin dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 605-612.
14. Ngo HTT, Tait RJ, Hulse GK: Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implant. Arch Gen Psychiatry. 2008; 65: 457-465.
15. Tait RJ, Ngo HTT, Hulse GK. Mortality in heroin users three years post implant naltrexone or methadone maintenance treatment. J Subst Abuse Treat. 2008; 35: 116-124.
16. Hulse GK, Basso MR: The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000; 19: 41-48.
17. Hulse GK, Arnold-Reed DE, O'Neil G, et al. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: Comparing two naltrexone implants. Addict Biol. 2004; 9: 59-65.
18. Ngo HT, Arnold-Reed DE, Hansson RC, et al.: Blood naltrexone levels over time following naltrexone implants. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 23-28.
19. Comer SD, Collins ED, Kleber HD, et al.: Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002; 159: 351-360.
20. Navaratnam V, Jamaludin A, Raman N, et al.: Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. 1994; 34: 231-236.
21. Chiang CN, Hollister LE, Gillespie HK, et al.: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. 1985; 16: 1-8.
22. Holman CDJ, Bass AJ, Rouse IL, et al.: Population-based linkage of health records in Western Australia: Development of a health services research linked database. Aust N Z J Pub Health. 1999; 23: 453-459.
23. Lawrence D, Holman CD, Jablenski A, et al.: Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry. 2003; 182: 31-36.
24. Valinsky LJ, Hockey RL, Hobbs MS, et al.: Finding bile duct injuries using record linkage: A validated study of complications following cholecystectomy. J Clin Epidemiol. 1999; 52: 893-901.
25. Data Linkage Unit, Statistical Summary. Available at http://www.publichealth.uwa.edu.au/welcome/research/dlu/linkage/ stats. Accessed May 9, 2005.
26. Therapeutic Goods Administration: Access to Unapproved Therapeutic Goods - The Special Access Scheme (SAS). Canberra: Commonwealth Department of Health and Aged Care, 2001.
27. World Health Organization: International Classification of Diseases and Health Related Problems: 10th Revision. Geneva: WHO, 1992.
28. World Health Organization: International Classification of Diseases and Health Related Problems: 9th Revision: Clinical Modification. Geneva: WHO; 1986.
29. World Health Organization: International Classification of Diseases, 9th Revision. Geneva: WHO; 1977.
30. Kaya C, Tugai Y, Filar J, et al.: Heroin users in Australia: Population trends. Drug Alcohol Rev. 2004;23:107-116.
31. Catalano RF, Hawkins JD, Wells EA, et al.: Evaluation of the effectiveness of adolescent drug abuse treatment, assessment of risks for relapse, and promising approaches for relapse prevention. Int J Addict. 1990; 25: 1085-1140.
32. Brewer DD, Catalano RF, Haggerty K, et al.: A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction [Review]. Addiction. 1998; 93: 73-92.
33. DiClemente C: Motivational interviewing and the stages of change. In Miller WR, Rollnick S (eds.): Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991: 191-202.
34. Verebey K, Volavka J, Mule SJ, et al.: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976; 20: 315-328.
35. Darke S, Ross J, Zador D, et al.: Heroin-related deaths in New South Wales, Australia, 1992-1996. Drug Alcohol Depend. 2000; 60: 141-150.
36. McGregor C, Darke S, Ali R, et al.: Experience of non-fatal over-dose among heroin users in Adelaide, Australia - Circumstances and risk perceptions. Addiction. 1998; 93: 701-711.
37. Hulse GK, Tait RJ: A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high risk' adolescent heroin users. Addict Biol. 2003; 8: 337-342.
38. Longo MC, Henry-Edwards SM, Humeniuk RE, et al.: Impact of the heroin 'drought' on patterns of drug use and drug-related harms. Drug Alcohol Rev. 2004; 23: 143-150.